Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pediatric Radiology
Published in: Pediatric Radiology 2/2020

01-02-2020 | Magnetic Resonance Imaging | Original Article

The impact of 18F-FDG PET on initial staging and therapy planning of pediatric soft-tissue sarcoma patients

Authors: Alaa Elmanzalawy, Reza Vali, Govind B. Chavhan, Abha A. Gupta, Yusuf Omarkhail, Afsaneh Amirabadi, Amer Shammas

Published in: Pediatric Radiology | Issue 2/2020

Login to get access

Abstract

Background

Soft-tissue sarcomas in children are a histologically heterogenous group of malignant tumors accounting for approximately 7% of childhood cancers. There is a paucity of data on the value of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) for initial staging and whether PET influenced management of these patients.

Objective

The aim of this analysis is to assess the use of 18F-FDG PET exclusively, and as a supplement to cross-sectional imaging in comparison to typical imaging protocols (CT and magnetic resonance imaging [MRI]) for initial staging as well as therapy planning in pediatric soft-tissue sarcoma patients.

Materials and methods

The list of 18F-FDG PET/CT performed for soft-tissue sarcoma between March 2007 and October 2017 was obtained from the Hospital Information System database. Twenty-six patients who had received 18F-FDG PET, MRI and/or CT at initial diagnosis were included in the study. 18F-FDG PET and concurrent diagnostic CT and MRI at initial staging were independently reviewed to note the number of primary and metastatic lesions detected by each modality. A chart review was conducted to collect information on final diagnosis, staging and treatment plan.

Results

During the study period, 26 patients (15 females) ages 1.3–17.9 years (median age: 6 years) had received 18F-FDG PET/CT at initial diagnosis of soft-tissue sarcoma. Diagnostic CT was available for comparison in all 26 patients and MRI was available in 18 patients. The mean interval between cross-sectional imaging and 18F-FDG PET was 5.9 days (range: 0–30 days). All 26 primary lesions were equally detected by 18F-FDG PET compared to CT and MRI. From 84 metastatic lesions, 16 were detected by PET as well as CT and MRI, 12 by 18F-FDG PET only (included mainly lymph node metastases) and 56 by CT and MRI only (included mainly lung metastases). 18F-FDG PET changed therapy planning in 5 patients out of 26 (19%) by showing additional lesions not detected by CT and MRI.

Conclusion

18F-FDG PET proved to be a valuable tool for precise initial staging of pediatric soft-tissue sarcoma patients, especially in detecting lymph node metastasis, and could be included in their initial work-up. Given the relative rarity and heterogeneity of this group of tumors, additional investigations are required to definitely establish a role for 18F-FDG PET in the initial staging and therapy planning of soft-tissue sarcoma in the pediatric population.
Literature
1.
2.
Spunt SL, Skapek SX, Coffin CM (2008) Pediatric nonrhabdomyosarcoma soft tissue sarcomas. Oncologist 13:668–678PubMed
3.
Paulino AC, Okcu MF (2008) Rhabdomyosarcoma. Curr Probl Cancer 32:7–34PubMed
4.
Eugene T, Corradini N, Carlier T et al (2012) 18F-FDG-PET/CT in initial staging and assessment of early response to chemotherapy of pediatric rhabdomyosarcomas. Nucl Med Commun 33:1089–1095PubMed
5.
Völker T, Denecke T, Steffen I et al (2007) Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 25:5435–5441PubMed
6.
Krasin MJ, Rodriguez-Galindo C, Billups CA et al (2004) Definitive irradiation in multidisciplinary management of localized Ewing sarcoma family of tumors in pediatric patients: outcome and prognostic factors. Int J Radiat Oncol Biol Phys 60:830–838PubMed
7.
Weeden S, Grimer RJ, Cannon SR et al (2001) The effect of local recurrence on survival in resected osteosarcoma. Eur J Cancer 37:39–46PubMed
8.
Chisholm JC, Marandet J, Rey A et al (2011) Prognostic factors after relapse in nonmetastatic rhabdomyosarcoma: a nomogram to better define patients who can be salvaged with further therapy. J Clin Oncol 29:1319–1325PubMed
9.
Weiss AR, Lyden ER, Anderson JR et al (2013) Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children’s Oncology Group Soft Tissue Sarcoma Committee. J Clin Oncol 31:3226–3232PubMedPubMedCentral
10.
Schoot RA, McHugh K, van Rijn RR et al (2013) Response assessment in pediatric rhabdomyosarcoma: can response evaluation criteria in solid tumors replace three-dimensional volume assessments? Radiology 269:870–878PubMed
11.
Norman G, Fayter D, Lewis-Light K et al (2015) An emerging evidence base for PET-CT in the management of childhood rhabdomyosarcoma: systematic review. BMJ Open 5:e006030–e006030PubMedPubMedCentral
12.
Schuetze SM (2006) Utility of positron emission tomography in sarcomas. Curr Opin Oncol 18:369–373PubMed
13.
Schuetze SM, Rubin BP, Vernon C et al (2005) Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 103:339–348PubMed
14.
Lucas JD, O’Doherty MJ, Cronin BF et al (1999) Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography. Br J Surg 86:550–556PubMed
15.
Franzius C, Sciuk J, Daldrup-Link HE et al (2000) FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy. Eur J Nucl Med 27:1305–1311PubMed
16.
Györke T, Zajic T, Lange A et al (2006) Impact of FDG PET for staging of Ewing sarcomas and primitive neuroectodermal tumours. Nucl Med Commun 27:17–24PubMed
17.
Franzius C, Daldrup-Link HE, Sciuk J et al (2001) FDG-PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol 12:479–486PubMed
18.
Klem ML, Grewal RK, Wexler LH et al (2007) PET for staging in rhabdomyosarcoma: an evaluation of PET as an adjunct to current staging tools. J Pediatr Hematol Oncol 29:9–14PubMed
19.
Kneisl JS, Patt JC, Johnson JC, Zuger JH (2006) Is PET useful in detecting occult nonpulmonary metastases in pediatric bone sarcomas? Clin Orthop Relat Res 450:101–104PubMed
20.
Dong Y, Zhang X, Wang S et al (2017) 18F-FDG PET/CT is useful in initial staging, restaging for pediatric rhabdomyosarcoma. Q J Nucl Med Mol Imaging 61:438–446PubMed
21.
22.
Vali R, Punnett A, Bajno L et al (2015) The value of 18 F-FDG PET in pediatric patients with post-transplant lymphoproliferative disorder at initial diagnosis. Pediatr Transplant 19:932–939PubMed
23.
Sathiakumar C, Som S, Eberl S, Lin P (2010) NEMA NU 2-2001 performance testing of a Philips Gemini GXL PET/CT scanner. Australas Phys Eng Sci Med 33:199–209PubMed
24.
Ludwig BJ, Wang J, Nadgir RN et al (2012) Imaging of cervical lymphadenopathy in children and young adults. AJR Am J Roentgenol 199:1105–1113PubMed
25.
Lang S, Kansy B (2014) Cervical lymph node diseases in children. GMS Curr Top Otorhinolaryngol Head Neck Surg 13:Doc08
26.
27.
Wagner LM, Kremer N, Gelfand MJ et al (2017) Detection of lymph node metastases in pediatric and adolescent/young adult sarcoma: sentinel lymph node biopsy versus fludeoxyglucose positron emission tomography imaging-a prospective trial. Cancer 123:155–160PubMed
28.
Huh J, Kim KW, Park SJ et al (2015) Imaging features of primary tumors and metastatic patterns of the extraskeletal Ewing sarcoma family of tumors in adults: a 17-year experience at a single institution. Korean J Radiol 16:783–790PubMedPubMedCentral
29.
Kim SG, Friedman K, Patel S, Hagiwara M (2016) Potential role of PET/MRI for imaging metastatic lymph nodes in head and neck cancer. AJR Am J Roentgenol 207:248–256PubMedPubMedCentral
30.
Christensen JA, Nathan MA, Mullan BP et al (2006) Characterization of the solitary pulmonary nodule: 18 F-FDG PET versus nodule-enhancement CT. AJR Am J Roentgenol 187:1361–1367PubMed
31.
Uslu L, Donig J, Link M et al (2015) Value of 18F-FDG PET and PET/CT for evaluation of pediatric malignancies. J Nucl Med 56:274–286PubMed
32.
Federico SM, Spunt SL, Krasin MJ et al (2013) Comparison of PET-CT and conventional imaging in staging pediatric rhabdomyosarcoma. Pediatr Blood Cancer 60:1128–1134PubMed
33.
Tateishi U, Hosono A, Makimoto A et al (2009) Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma. Ann Nucl Med 23:155–161PubMed
34.
Ricard F, Cimarelli S, Deshayes E et al (2011) Additional benefit of F-18 FDG PET/CT in the staging and follow-up of pediatric rhabdomyosarcoma. Clin Nucl Med 36:672–677PubMed
35.
Baum SH, Fruhwald M, Rahbar K et al (2011) Contribution of PET/CT to prediction of outcome in children and young adults with rhabdomyosarcoma. J Nucl Med 52:1535–1540PubMed
36.
Harrison DJ, Parisi MT, Shulkin BL (2017) The role of 18 F-FDG-PET/CT in pediatric sarcoma. Semin Nucl Med 47:229–241PubMed
37.
Torabi M, Aquino SL, Harisinghani MG (2004) Current concepts in lymph node imaging. J Nucl Med 45:1509–1518PubMed
38.
Golder WA (2004) Lymph node diagnosis in oncologic imaging: a dilemma still waiting to be solved. Onkologie 27:194–199PubMed
39.
Cormier JN, Pollock RE (2004) Soft tissue sarcomas. CA Cancer J Clin 54:94–109PubMed
40.
Vincenzi B, Frezza AM, Schiavon G et al (2013) Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options. Clin Sarcoma Res 3:6PubMedPubMedCentral
41.
Billingsley KG, Burt ME, Jara E et al (1999) Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg 229:602–610PubMedPubMedCentral
42.
Rodeberg D, Paidas C (2006) Childhood rhabdomyosarcoma. Semin Pediatr Surg 15:57–62PubMed
43.
Zhang J, Maniawski P, Knopp MV (2018) Performance evaluation of the next generation solid-state digital photon counting PET/CT system. EJNMMI Res 8:97PubMedPubMedCentral
Metadata
Title
The impact of 18F-FDG PET on initial staging and therapy planning of pediatric soft-tissue sarcoma patients
Authors
Alaa Elmanzalawy
Reza Vali
Govind B. Chavhan
Abha A. Gupta
Yusuf Omarkhail
Afsaneh Amirabadi
Amer Shammas
Publication date
01-02-2020
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Radiology / Issue 2/2020
Print ISSN: 0301-0449
Electronic ISSN: 1432-1998
DOI
https://doi.org/10.1007/s00247-019-04530-1

Other articles of this Issue 2/2020

Pediatric Radiology 2/2020 Go to the issue

Editorial

Pediatric Radiology editorial board — acknowledgments and updates

Original Article

Capturing infant swallow impairment on videofluoroscopy: timing matters

Case Report

Imaging diagnosis of epipericardial fat necrosis in children

Hermes

Hermes

PEDIATRIC RADIOLOGY CME ACTIVITY

Pediatric Radiology continuing medical education activity

Original Article

Altered regional myocardial velocities by tissue phase mapping and feature tracking in pediatric patients with hypertrophic cardiomyopathy